Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Neratinib Plus Chemotherapy Improved PFS in HER2+ Breast Cancer With CNS Involvement


Targeted Oncology - Neratinib plus capecitabine improved progression-free survival and time to intervention for central nervous system disease in patients with previously treated HER2-positive metastatic breast cancer
  • The combination of neratinib and capecitabine improved progression-free survival and time to intervention for CNS disease in patients with previously treated HER2-positive metastatic breast cancer. https://t.co/K20kvpJWrw #breastcancer #bcsm